AbbVie Inc. is a global, diversified research-based biopharmaceutical company with leadership positions across several therapeutic areas, including immunology, oncology, aesthetics, neuroscience, and eye care . The company operates as a single global business segment dedicated to the research, development, manufacturing, commercialization, and sale of innovative medicines and therapies . AbbVie's product portfolio includes blockbuster products such as Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox, Juvederm, Vraylar, Ubrelvy, and Qulipta, among others .
- Immunology - Develops and markets treatments for autoimmune diseases, with key products including Humira, Skyrizi, and Rinvoq.
- Oncology - Focuses on cancer treatment solutions, featuring products like Imbruvica and Venclexta.
- Neuroscience - Offers therapies for neurological disorders, with significant products such as Vraylar and Botox Therapeutic.
- Aesthetics - Provides cosmetic products and treatments, including Botox and Juvederm.
- Eye Care - Engages in the development and sale of treatments for various eye conditions.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Robert A. Michael ExecutiveBoard | Chief Executive Officer | None | CEO since July 1, 2024; joined AbbVie in 2013; previously President and COO; key leader in AbbVie’s growth and strategy, including major acquisitions like Allergan. | View Report → |
Azita Saleki-Gerhardt Executive | Executive Vice President, Chief Operations Officer | Board Member at Entegris Inc. | Joined Abbott in 1993; transitioned to AbbVie in 2013; oversees global operations and ESG initiatives; instrumental in achieving carbon emissions targets. | |
David R. Purdue Executive | Senior Vice President, Controller (effective March 1, 2025) | None | Joined Abbott in 2003; transitioned to AbbVie; previously VP, Controller, Commercial Operations; succeeding Kevin K. Buckbee as Controller. | |
Jeffrey R. Stewart Executive | Executive Vice President, Chief Commercial Officer | None | Joined Abbott in 1992; transitioned to AbbVie in 2013; oversees global commercial operations and patient access programs. | |
Kevin K. Buckbee Executive | Senior Vice President, Controller | None | Joined Abbott in 1991; transitioned to AbbVie in 2013; retiring effective March 1, 2025; succeeded by David R. Purdue. | |
Nicholas J. Donoghoe Executive | Executive Vice President, Chief Business and Strategy Officer | None | Joined AbbVie in 2019; previously SVP, R&D Operations; former McKinsey Partner; key leader in portfolio innovation and Allergan integration. | |
Perry C. Siatis Executive | Executive Vice President, General Counsel, and Secretary | None | Joined Abbott in 2005; transitioned to AbbVie in 2013; oversees legal strategy, compliance, and intellectual property. | |
Roopal Thakkar Executive | Executive Vice President, Research & Development, and Chief Scientific Officer | None | Joined Abbott/AbbVie in 2003; leads global R&D organization with over 14,000 team members; oversees pipeline of 90+ drug/device programs. | |
Scott T. Reents Executive | Executive Vice President, Chief Financial Officer | None | CFO since June 2022; joined AbbVie in 2013; previously VP, Tax and Treasury; instrumental in financial strategy and compliance. | |
Timothy J. Richmond Executive | Executive Vice President, Chief Human Resources Officer | None | Joined AbbVie in 2013; oversees HR strategy, including talent acquisition and organizational development. | |
Brett J. Hart Board | Director | President of United Airlines Holdings, Inc. | Director since 2016; brings expertise in risk management, legal strategy, and corporate governance from his leadership roles at United Airlines. | |
Edward J. Rapp Board | Director | Director at Xos, Inc.; Member of University of Missouri College of Business Advisory Board | Director since 2013; former Group President and CFO at Caterpillar; expertise in global operations and sustainability. | |
Frederick H. Waddell Board | Director | Director at IBM | Director since 2013; former CEO of Northern Trust; expertise in financial services and governance. | |
Glenn F. Tilton Board | Director | Director at Phillips 66 | Director since 2013; former lead independent director (2013–2024); extensive experience in governance and finance from leadership roles at United Airlines and Texaco. | |
Jennifer L. Davis Board | Director | CEO, Health Care at Procter & Gamble | Appointed director in October 2023; brings expertise in marketing, corporate strategy, and healthcare operations from her career at P&G. | |
Melody B. Meyer Board | Director | President of Melody Meyer Energy, LLC; Board Member at bp p.l.c. | Director since 2017; extensive experience in operations, sustainability, and energy sector leadership. | |
Rebecca B. Roberts Board | Director | Director at Black Hills Corporation and MSA Safety Incorporated | Director since 2018; former President of Chevron Pipe Line Company; expertise in operations, safety, and regulatory matters. | |
Richard A. Gonzalez Board | Executive Chairman of the Board | None | Founding CEO of AbbVie (2013–2024); transitioned to Executive Chairman on July 1, 2024; led AbbVie’s market cap growth to over $300 billion. | |
Robert J. Alpern Board | Director | Ensign Professor at Yale School of Medicine; Director at Tricida, Inc. | Director since 2013; brings medical and scientific expertise; former Dean of Yale School of Medicine. | |
Roxanne S. Austin Board | Lead Independent Director | President of Melody Meyer Energy, LLC; Board Member at bp p.l.c. | Director since 2013; appointed Lead Independent Director on July 1, 2024; extensive experience in corporate governance and finance. | |
Susan E. Quaggin Board | Director | Chair of Medicine at Northwestern University; Director of Feinberg Cardiovascular and Renal Research Institute | Appointed director in October 2023; brings medical and scientific expertise; former President of the American Society of Nephrology. | |
Thomas C. Freyman Board | Director | None | Director since 2020; former EVP, Finance and Administration at Abbott; expertise in finance and risk oversight. | |
William H.L. Burnside Board | Director | None | Director since 2013; retired Senior VP at Boston Consulting Group; expertise in corporate finance and strategic advisory. |
-
Given the ongoing economic challenges in China that have significantly impacted Juvederm's performance, particularly within the Aesthetics segment, what specific strategies does AbbVie have to navigate these headwinds and stimulate growth in this critical market?
-
With the recent $100 million downward adjustment in VRAYLAR's full-year sales guidance due to channel mix pressures and negative pricing impact, can you elaborate on the factors leading to this shift and how you plan to mitigate similar issues moving forward?
-
In the competitive immunology space, your head-to-head trial of SKYRIZI against ENTYVIO aims for potential superiority in endoscopic improvement for ulcerative colitis patients; what gives you confidence in achieving this outcome, and what are the implications if the trial does not meet its superiority endpoints?
-
As SKYRIZI and RINVOQ continue to drive significant growth, what challenges do you foresee in maintaining their momentum across existing indications, and how do you plan to address potential competition from new market entrants and evolving treatment paradigms?
-
With the integration of Cerevel Therapeutics and the upcoming pivotal study readouts for emraclidine in schizophrenia, how is AbbVie preparing to compete against existing therapies, especially considering recent approvals with safety considerations like hepatic monitoring, and what are your expectations regarding emraclidine's safety and efficacy profile?
Research analysts who have asked questions during AbbVie earnings calls.
Mohit Bansal
Wells Fargo & Company
6 questions for ABBV
Steve Scala
Cowen
6 questions for ABBV
Vamil Divan
Guggenheim Securities
6 questions for ABBV
Terence Flynn
Morgan Stanley
4 questions for ABBV
Asad Haider
Goldman Sachs
3 questions for ABBV
Carter L. Gould
Barclays
3 questions for ABBV
Chris Schott
JPMorgan Chase & Co.
3 questions for ABBV
Christopher Schott
JPMorgan Chase & Co.
3 questions for ABBV
Courtney Breen
AllianceBernstein
3 questions for ABBV
David Risinger
Leerink Partners
3 questions for ABBV
Geoffrey Meacham
Citi
3 questions for ABBV
Luisa Hector
Berenberg
3 questions for ABBV
Trung Huynh
UBS Group AG
3 questions for ABBV
Chris Shibutani
Goldman Sachs Group, Inc.
2 questions for ABBV
Dave Risinger
Leerink Partners
2 questions for ABBV
Geoff Meacham
Citigroup Inc.
2 questions for ABBV
James Shin
Analyst
2 questions for ABBV
Matt Phipps
William Blair
2 questions for ABBV
Simon Baker
Rothschild & Co Redburn
2 questions for ABBV
Terrence Flynn
Morgan Stanley
2 questions for ABBV
Timothy Anderson
BofA Securities
2 questions for ABBV
Alexandria Hammond
Wolfe Research
1 question for ABBV
Christopher Raymond
Piper Sandler
1 question for ABBV
David Amsellem
Piper Sandler Companies
1 question for ABBV
David Aslam
Piper Sandler
1 question for ABBV
Evan Seigerman
BMO Capital Markets
1 question for ABBV
Gary Nachman
Raymond James
1 question for ABBV
Jon Win
UBS
1 question for ABBV
Tim Anderson
Bank of America
1 question for ABBV
| Customer | Relationship | Segment | Details |
|---|---|---|---|
McKesson Corporation | Wholesale distributor | US Pharmaceuticals | Accounts for <39% of 2024 US gross revenues ; collectively with the other two wholesalers, they represent substantially all US pharma sales. |
Cardinal Health, Inc. | Wholesale distributor | US Pharmaceuticals | Accounts for <39% of 2024 US gross revenues ; collectively with the other two wholesalers, they represent substantially all US pharma sales. |
Cencora, Inc. | Wholesale distributor | US Pharmaceuticals | Accounts for <39% of 2024 US gross revenues ; collectively with the other two wholesalers, they represent substantially all US pharma sales. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Nimble Therapeutics | 2025 | AbbVie completed its acquisition of Nimble Therapeutics in January 2025 by paying $200 million upfront with potential milestone payments up to $130 million, aiming to enhance its immunology R&D pipeline with an investigational oral peptide IL23R inhibitor and a proprietary peptide synthesis platform. |
ImmunoGen, Inc. | 2024 | AbbVie acquired ImmunoGen, Inc. in February 2024 for approximately $9.8 billion in total value, strengthening its oncology portfolio with antibody-drug conjugate (ADC) technology including the first-in-class product ELAHERE for platinum-resistant ovarian cancer. |
Cerevel Therapeutics Holdings, Inc. | 2024 | Completed on August 1, 2024, the acquisition of Cerevel Therapeutics involved a cash payment of $45.00 per share, totaling about $8.7 billion, and strategically expanded AbbVie's neuroscience portfolio while integrating a licensing agreement with Pfizer that could trigger additional milestone payments up to $1.6 billion. |
Syndesi Therapeutics SA | 2022 | Acquired in February 2022 for an upfront payment of $130 million with contingent future payments up to $870 million, this deal provided AbbVie access to Syndesi's SV2A modulator portfolio, including the lead molecule SDI-118 in Phase 1b studies aimed at enhancing synaptic efficiency. |
DJS Antibodies Ltd | 2022 | In 2022, AbbVie acquired DJS Antibodies Ltd for approximately $255 million upfront plus up to $95 million in future milestone payments, obtaining the DJS-002 LPAR1 antagonist antibody program and the HEPTAD platform for novel antibody discovery targeting fibrotic diseases. |
Recent press releases and 8-K filings for ABBV.
- Genmab and AbbVie will present over 20 epcoritamab abstracts, including seven oral presentations, at the ASH Annual Meeting (Dec 6–9).
- Data highlight epcoritamab’s potential in first- and second-line follicular lymphoma and first-line diffuse large B-cell lymphoma.
- Phase 3 EPCORE FL-1 trial results (epcoritamab + rituximab + lenalidomide) in relapsed/refractory FL accepted for an oral presentation.
- Genmab will host a 2025 R&D Update and ASH Data Review webcast on December 11.
- AbbVie delivered adjusted EPS of $1.86 and net revenues of $15.8 billion in Q3, up 8.4% operationally, beating guidance; raised 2025 EPS to $10.61–$10.65 and sales to $60.9 billion, with Q4 revenue and EPS guidance at $16.3 billion+ and $3.32–$3.36
- Immunology revenues grew 11.2% to $7.9 billion, led by SKYRIZI ($4.7 billion, +46% op) and RINVOQ ($2.2 billion, +34.1% op), offsetting HUMIRA’s 55.7% decline to $993 million; neuroscience sales rose 19.6% to $2.8 billion, with VYALEV up 40% to $138 million
- Invested $84 billion in R&D since 2013, plans $9 billion of 2025 R&D expense, and maintains ~90 pipeline programs; key upcoming catalysts include tavapadon, PVEK approvals, expanded indications for RINVOQ/EPKINLY/QULIPTA/UBRELVY, and late-stage data for lutikizumab and Temab-A
- Generated $13 billion of free cash flow YTD Q3 (cash $5.6 billion), increased quarterly dividend by 5.5% to $1.73 (payable Feb 2026), and acquired Gilgamesh (bretisilocin) and Capstan to expand immunology and psychiatry pipelines
- AbbVie delivered adjusted EPS of $1.86, $0.10 above guidance, with net revenues of $15.8 billion (+8.4% operationally), driven by strong immunology and neuroscience performance.
- Immunology revenues reached $7.9 billion (+11.2%), led by SKYRIZI $4.7 billion (+46%) and RINVOQ $2.2 billion (+34.1%), while Humira sales declined 55.7% to $993 million.
- Raised full-year 2025 guidance to $10.61–$10.65 adjusted EPS and $60.9 billion net revenues, reflecting upgraded forecasts for SKYRIZI and neuroscience.
- Increased quarterly dividend 5.5% to $1.73 per share (payable Feb 2026), supported by $13 billion free cash flow and planned $10 billion U.S. capital investment over 10 years.
- Advanced pipeline with positive phase 3 RINVOQ data in alopecia areata and vitiligo, FDA submission for PVEC in BPDCN, and acquisitions of Capstan’s CAR-T platform and Gilgamesh’s bredacillicin.
- AbbVie reported Q3 adjusted EPS of $1.86, $0.10 above guidance, on total net revenues of $15.8 billion, up 8.4% operationally; raised full-year 2025 adjusted EPS guidance to $10.61–$10.65 and sales guidance to $60.9 billion.
- Immunology sales reached $7.9 billion (+11.2% op), led by SKYRIZI at $4.7 billion (+46%) and RINVOQ at $2.2 billion (+34.1%); neuroscience grew 19.6% to $2.8 billion, oncology was flat at $1.7 billion, and aesthetics declined 4.2% to $1.2 billion.
- Investing $9 billion in R&D for 2025 to support ~90 pipeline programs; announced positive phase 3 RINVOQ results in alopecia areata and vitiligo, submitted PVEC for BPDCN, and advancing novel ADCs and in vivo CAR-T platforms.
- Increased the quarterly dividend by 5.5% to $1.73 per share starting February 2026; generated ~$13 billion free cash flow YTD and targets a net leverage ratio of two times by end-2026.
- AbbVie delivered third-quarter net revenues of $15.776 B, up 9.1% reported and 8.4% operationally.
- GAAP diluted EPS was $0.10, an 88.6% decrease, and adjusted diluted EPS was $1.86, down 38.0%.
- Immunology portfolio net revenues grew 11.9% reported to $7.885 B (11.2% operational); neuroscience portfolio net revenues increased 20.2% reported to $2.841 B (19.6% operational).
- Raised full-year 2025 adjusted diluted EPS guidance to $10.61–$10.65, from $10.38–$10.58.
- Declared a 5.5% dividend increase to $1.73 per share, beginning February 17, 2026.
- AbbVie delivered third-quarter net revenues of $15.776 billion, up 9.1 percent reported (8.4 percent operational) versus prior year.
- GAAP diluted EPS was $0.10, down 88.6 percent, and adjusted diluted EPS was $1.86, down 38.0 percent, reflecting a $1.50 per-share impact from acquired IPR&D and milestones expense.
- The company raised its full-year 2025 adjusted diluted EPS guidance to $10.61–$10.65, up from $10.38–$10.58.
- AbbVie declared a 5.5 percent dividend increase, raising the quarterly payout from $1.64 to $1.73 per share, effective with the February 17, 2026 payment.
- In two replicate Phase 3 studies, upadacitinib (RINVOQ 15 mg QD) achieved both co-primary endpoints—≥50% reduction in total vitiligo (T-VASI 50) and ≥75% reduction on the face (F-VASI 75) at week 48 vs placebo in adult and adolescent NSV patients.
- Study 1 outcomes: T-VASI 50 was 19.4% vs 5.9% and F-VASI 75 was 25.2% vs 5.9%; Study 2: T-VASI 50 was 21.5% vs 5.9% and F-VASI 75 was 23.4% vs 6.9% for upadacitinib vs placebo.
- Safety profile aligned with approved indications; most frequent TEAEs were upper respiratory tract infection, acne and nasopharyngitis, with no new safety signals, MACE or VTE reported.
- These results address a high unmet need—no approved systemic therapies exist for vitiligo—and support AbbVie’s expansion in immunology.
- SELECT-SWITCH Phase 3b/4 trial compared upadacitinib 15 mg QD versus adalimumab 40 mg Q2W in adults with moderate to severe rheumatoid arthritis who failed a first TNF inhibitor.
- 43.3% of patients on upadacitinib achieved low disease activity (DAS28-CRP ≤ 3.2) versus 22.4% on adalimumab at week 12 (p < 0.001).
- 28.4% of upadacitinib-treated patients reached remission (DAS28-CRP < 2.6) compared to 14.5% with adalimumab at week 12 (p < 0.001).
- Safety was consistent with known profiles, with no new risks and similar serious adverse event rates (2.0% upadacitinib vs 2.4% adalimumab) over 12 weeks.
- AbbVie (NYSE: ABBV) completed the acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin, expanding its psychiatry pipeline.
- Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist currently in Phase 2 development for moderate-to-severe major depressive disorder.
- The deal underscores AbbVie’s strategy to bolster its neuroscience portfolio and accelerate development of next-generation mental health therapies.
- Enveric Biosciences has engaged Fish & Richardson P.C. to defend its U.S. Patent No. 12,138,276, which includes claims potentially relevant to Bretisilocin (GM-2505) in clinical trials, recently acquired by AbbVie for up to $1.2 billion on August 25, 2025.
- The ’276 patent family comprises one issued U.S. patent, additional issued and pending U.S. applications, plus international filings in Australia, Canada, China, Europe, Japan, Mexico, and South Korea, but does not cover Enveric’s proprietary EB-003 program.
- Enveric’s broader IP estate includes 26 issued U.S. patents and 60 pending national and international applications across five programs.
- Through out-licensing agreements, Enveric is eligible to receive up to $205 million in upfront, development, and sales milestones, plus royalties on future sales.